Novel PCSK9 Inhibitor Reduced LDL by 50%
Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.
Source: medscape.com
Scientific Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Scientific Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Scientific Session Today - Breaking & Trending Today
Tirzepatide Demonstrates Reduction in Sleep Apnea-Relate Events
Eli Lilly and Company will submit results of the study to support tirzepatide (Zepbound) for treatment of obstructive sleep apnea later this year.
Source: pharmacytimes.com
Complete Revasc Not Superior to Culprit-Only PCI After MI
In patients with STEMI and multivessel disease, FFR-guided complete nonculprit revascularization did not reduce events vs culprit lesion-only PCI in the FULL-REVASC trial.
Source: medscape.com
Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity
The PROACT trial assessing enalapril in patients with cancer undergoing chemotherapy showed this approach did not affect cardiac function or the rate of cardiac injury.
Source: medscape.com
Preventive PCI for Vulnerable Plaques Reduces Cardiac Events
Preventive PCI plus optimal medical therapy reduced cardiac events and death in patients with non–flow-limiting coronary plaques vs medical therapy.
Source: medscape.com